Long Focus Capital Management LLC boosted its position in Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) by 123.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,537,774 shares of the company's stock after buying an additional 1,404,228 shares during the period. Aura Biosciences makes up approximately 0.7% of Long Focus Capital Management LLC's investment portfolio, making the stock its 25th largest holding. Long Focus Capital Management LLC owned 5.08% of Aura Biosciences worth $20,861,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Price T Rowe Associates Inc. MD increased its stake in shares of Aura Biosciences by 7.9% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 556,941 shares of the company's stock worth $4,579,000 after purchasing an additional 40,815 shares in the last quarter. Harvest Investment Services LLC acquired a new position in Aura Biosciences in the 4th quarter valued at $133,000. B Group Inc. purchased a new position in Aura Biosciences in the 4th quarter valued at $3,885,000. Dimensional Fund Advisors LP boosted its stake in Aura Biosciences by 25.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 365,824 shares of the company's stock worth $3,007,000 after purchasing an additional 73,062 shares during the last quarter. Finally, Barclays PLC boosted its stake in Aura Biosciences by 19.2% during the 4th quarter. Barclays PLC now owns 72,725 shares of the company's stock worth $598,000 after purchasing an additional 11,715 shares during the last quarter. Institutional investors and hedge funds own 96.75% of the company's stock.
Aura Biosciences Price Performance
NASDAQ AURA traded up $0.04 on Monday, hitting $5.42. 50,003 shares of the company's stock were exchanged, compared to its average volume of 201,688. The firm has a market cap of $272.17 million, a price-to-earnings ratio of -3.12 and a beta of 0.43. The firm's 50-day moving average price is $6.48 and its two-hundred day moving average price is $8.05. Aura Biosciences, Inc. has a fifty-two week low of $4.84 and a fifty-two week high of $12.38.
Aura Biosciences (NASDAQ:AURA - Get Free Report) last issued its quarterly earnings data on Monday, March 24th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.09). On average, research analysts predict that Aura Biosciences, Inc. will post -1.66 earnings per share for the current fiscal year.
Insider Buying and Selling
In related news, insider Conor Kilroy sold 7,162 shares of the stock in a transaction on Wednesday, April 16th. The stock was sold at an average price of $5.49, for a total value of $39,319.38. Following the completion of the sale, the insider now directly owns 179,313 shares in the company, valued at approximately $984,428.37. This represents a 3.84 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last three months, insiders have sold 14,148 shares of company stock valued at $91,434. Insiders own 5.40% of the company's stock.
Wall Street Analysts Forecast Growth
Several brokerages recently issued reports on AURA. Lifesci Capital raised shares of Aura Biosciences to a "strong-buy" rating in a research note on Friday, January 31st. HC Wainwright set a $25.00 price target on Aura Biosciences in a report on Tuesday, March 25th. JMP Securities set a $19.00 price objective on Aura Biosciences in a research note on Wednesday, March 26th. Finally, Citigroup reaffirmed an "outperform" rating on shares of Aura Biosciences in a research note on Wednesday, March 26th. Six investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Aura Biosciences currently has a consensus rating of "Buy" and an average target price of $22.75.
Check Out Our Latest Report on Aura Biosciences
Aura Biosciences Company Profile
(
Free Report)
Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
Featured Articles
Before you consider Aura Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aura Biosciences wasn't on the list.
While Aura Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
